title: Reply to D. Przepiorka et al and M.K. Jensen.
authors.forename: Alan K
authors.initials: AK
authors.lastname: Burnett
authors.forename: Robert K
authors.initials: RK
authors.lastname: Hills
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality*
chemical_list: D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized